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ABSTRACT:
Introduction: There is no consensus on the first line medical treatment of Meniere disease to produce symptomatic 
improvement and slow the disease progress. Dietary salt restriction, diuretics, and vasodilators like betahistine are 
among the first line drugs that have been used for long. There is lack of evidence due to paucity of quality studies to 
support their effectiveness and advocate their use. This study is done to evaluate the effectiveness of three first line 
treatment of Meniere disease i.e. salt restriction, oral diuretics, and betahistine. Methods: Double blind randomized 
controlled trial was carried out in out-patient clinic of Ear Nose and Throat department of Lumbini Medical College 
Teaching Hospital. Cases were randomized into three groups; dietary salt restriction, diuretics as amiloride and 
furosemide, and vasodilator as betahistine. Pre and post treatment evaluation was done in terms of number and severity 
of vertigo, tinnitus, and hearing outcome. Results: There were a total of 97 cases with F:M ratio of 1.1:1. Mean age 
of patients was 47.86 yr (SD=12.7). Twenty-nine (30%) were treated with dietary sodium restriction alone (Group 
A), 35 (36%) were treated with diuretics (Group B) and the rest 33 (34%) were treated with vasodilator (betahistine, 
Group C). There was no significant difference in hearing outcome in any group. Tinnitus was significantly improved 
in Group B. Number of vertigo attack was significantly decreased in Group B and Group C. Severity of vertigo 
was significantly decreased in Group B. Conclusion: Dietary salt restriction alone was not effective in controlling 
any aspect of the disease whereas diuretics were effective in reducing tinnitus and number and severity of vertigo. 
Betahistine was effective in reducing the number of vertigo attacks but not effective on other aspects of the disease.
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INTRODUCTION:
 Meniere disease is the disease of inner 
ear characterized by endolymphatic hydrops. 
Clinically, the patients with this disease presents 
with characteristic features of episodic vertigo, ear 
fullness, tinnitus and fluctuating hearing loss. The 
disease is idiopathic. When the disease is secondary 
to a number of disorders, it is referred to as Meniere 
syndrome.1
 No treatment has been so far found to stop 
the disease process. There is no consensus on the 
first line medical treatment to produce symptomatic 
improvement and slow the disease progress. 
Various treatment has been tried with different 
outcome in several studies. Dietary salt restriction 
is one of the first line treatment for Meniere disease. 
Some advocate mild rather than harsh restriction. 
Sodium restriction is thought to lower pressure in 
the inner ear which in turn reduces the chances of 
membrane rupture. Sodium restriction also helps 
to lower systemic hypertension which is regarded 
as a vascular risk factor.2-4 Diuretics is another 
first line treatment for Meniere disease. Diuretics 
are believed to work by reducing the volume (and 
therefore also the pressure) of the inner ear fluids. 
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Despite the lack of high quality evidence, some 
studies have reported an improvement in patients' 
vertigo with diuretics.5 Oral betahistine is the most 
widely accepted treatment in Europe.6-8 Betahistine 
has a structural similarity to histamine and has a 
weak agonist effect on H1 and H2 receptors, but a 
strong antagonist effect on H3 receptors. It may have 
a beneficial effect upon endolymphatic hydrops by 
altering the microcirculation of organ of corti.6 A 
recent systematic review however, concluded that 
there is no evidence that betahistine is effective in 
patients with Meniere disease or syndrome.9 The 
second line treatment of Meniere disease includes the 
Meniett device, endolymphatic sac decompression, 
and intratympanic gentamicin injections.10
 This study is done to evaluate the effectiveness 
of three first line treatment of Meniere disease i.e. 
salt restriction, oral diuretics, and betahistine in 
terms of hearing outcome, number and severity of 
vertigo attacks, and tinnitus.
METHODS:
 This double blind randomized controlled 
trial was carried out in the out-patient clinic of Ear 
Nose Throat (ENT) department of Lumbini Medical 
College Teaching Hospital from May 2014 to July 
2016. In the last three months, follow-up evaluation 
was done and no new patients were enrolled. Ethical 
clearance was taken from the ethical and research 
committee of the College. 
 Patients were diagnosed according to AAO-
HNS 1995 guidelines.1 All the new cases or those 
diagnosed before but have not taken medicine for last 
three months were included in the study. The patients 
were evaluated clinically and, when indicated, 
with the investigations to rule out possible causes 
of Meniere syndrome. Special attention was given 
towards syphilis, thyroid disorders, auto-immune 
disorders like lupus and rheumatoid arthritis. 
 Patients who did not consent to study, could 
not come for follow up within three months, or those 
who were lost to follow up and could not be traced 
by various means were excluded from the study.
 All the patients were then evaluated for the 
number of vertigo attacks in the preceding three 
months, severity of vertigo attack and tinnitus rating 
according to visual analogue score with maximum 
score of 10 (VAS). We followed the same staging 
system as James et al. for evaluation of severity of 
vertigo.11 Vertigo was defined as mild when it was 
not accompanied by either nausea or vomiting with 
score of one, as moderate when it was accompanied 
by nausea but no vomiting with score of two and as 
severe when accompanied by vomiting with score of 
three. Hearing improvement was evaluated on basis 
of perceived improvement by the patients.
 The patients were randomly assigned into one 
of the three groups according to computer generated 
random numbers. Group A were given a tablet of 
vitamin B complex daily as a placebo and advised 
to reduce the salt intake in their diet. Group B were 
given a combination tablet of amiloride five mg and 
furosemide 40 mg to be taken every morning. They 
were not advised anything about the intake of salt. 
Group C were given a tablet of betahistine 24 mg at 
bedtime daily. They were also not advised anything 
about the salt intake. All patients were called for 
follow-up at six weeks to check if they were taking 
medicine regularly and had any problems, and then 
at next six weeks for re-evaluation. The persons 
involved in re-evaluation was blinded such that they 
were unaware to which group the patient belonged 
to. 
RESULTS:
 There were a total of 97 participants. Forty 
six (47.4%) were male and 51 (52.6%) were female 
with F:M ratio of 1.1:1. Assuming equal proportion 
of male and female in the population, this difference 
was not statistically significant (X2[N=97, df=1] 
= 0.26, p=0.6). Group-wise gender distribution is 
shown in Table 1. There was no significant difference 
of gender in any treatment group.
Table 1: Gender distribution in treatment group.
Group Male Female statistics
A 14 15 X2=0.3, p=0.85
B 15 20 X2=0.7, p=0.4
C 17 16 X2=0.3, p=0.86
 Mean age of the patients was 47.86 yr 
(SD=12.7). Mean age in Group A was 47.34 yr 
(SD=11.9), Group B was 45.77 yr (SD=13.2), and 
Group C was 50.5 yr (SD=12.7). This difference 
of age among the three groups was not statistically 
significant (F[N=97, df=2] = 1.2, p=0.3).  These data 
and statistics show that the patients were evenly 
distributed for age and gender among the three 
groups. 
 Of the total 97 patients, 29 (30%) were 
treated with dietary modification alone (Group A), 
35 (36%) were treated with diuretics (Group B) 
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and the rest 33 (34%) were treated with vasodilator 
(betahistine, Group C).
There was no significant difference in hearing 
outcome in any of the groups as shown in table 2.
Table 2: Hearing outcome
Hearing Outcome
Group worse same better
A 6 21 2
B 13 20 2
C 7 23 3
Total 26 64 7
p=0.55 by Fisher Exact Test (FET)
A Wilcoxon signed rank test was used 
to examine the pre-treatment and post-treatment 
tinnitus score in each treatment group.  There was 
no significant difference in tinnitus score in Group 
A (z = -0.5, p=0.6) and Group C (z = -1.1, p=0.26). 
However, there was a significant decrease in tinnitus 
score in post-treatment group in Group B (z = -2.2, 
p=0.03). Hence, tinnitus score was likely to be 
decreased significantly only by diuretics.
Similarly, a Wilcoxon signed rank test was 
used to examine the number of vertigo attack in pre 
and post-treatment group in each treatment category. 
There was a decrease in number of vertigo attack in 
Group A which was not significant (z = -1.8, p=0.07). 
Number of vertigo was significantly decreased in 
Group B (z = 5.1, p<.001) and Group C (z = -4, 
p<.001). Hence, number of vertigo attacks were 
likely to be reduced by diuretics or vasodilators but 
not by dietary restriction of salt alone.
Again, a Wilcoxon signed rank test was 
applied to see the difference in severity of vertigo 
in pre and post treatment group. Severity of vertigo 
was decreased in Group A (z = -1.7, p=.08) and 
Group C (z = -1.8, p=.07) but was not significant. 
It was significantly decreased in Group B (z = -4.2, 
p<.001). 
DISCUSSION:
Meniere disease is considered to be a disease 
of female. Alexender TH. et al. found that the F:M 
ratio of patients suffering from Meniere disease was 
1.89:1.12 Simo H. et al. found it to be 1.5:1.13 We found 
the F:M ratio to be 1.1:1. Though there was a female 
preponderance in out study, the difference was small 
and not significant. We do not have explanation 
for this decrease in female preponderance. We did 
not find any similar study done in our country to 
compare our results from the similar demography. 
Salt restriction has been mentioned as one 
of the first line of medical treatment of Meniere 
disease.2,3,4 Luxford E. et al. found an improvement 
in the number and severity of vertigo with dietary 
modification containing low sodium diet.14 Beneficial 
result of dietary sodium restriction has also been 
documented by Sheahan SL. et al. 15 Dietary sodium 
restriction has been advised by many clinicians as 
a first line treatment for Meniere disease.16,17 In our 
study, we found no benefit by dietary salt restriction 
in terms of hearing improvement, number of vertigo, 
severity of vertigo and tinnitus score. Dietary 
restriction is highly variable and is patient dependent. 
We believe the role of dietary modification, if 
any, does not depend only on reducing the sodium 
content. It may have complex relationship between 
several components like water restriction, amount of 
caffeine and alcohol consumption etc.
Diuretics has been mentioned by many 
studies to be effective for the treatment of Meniere 
disease.18,19 We found that diuretics were effective 
in significantly reducing the number and severity 
of vertigo and tinnitus score but were not effective 
in improving hearing outcome. Another study 
concluded that hydrops is not always associated with 
Meniere and should not to be considered its ultimate 
cause.20 Diuretics are believed to work by reducing 
the volume (and therefore also the pressure) of 
the inner ear fluids. A study found no evidence of 
endolymphatic hydrops modification one hour after 
intravenously administered frusemide.21 A Cochrane 
review of diuretics for Meniere disease failed to 
identify any trials that could be used to support their 
use.5 Hence, diuretics may be effective in controlling 
the symptoms of Meniere disease by unknown 
mechanisms other than reducing the labyrinthine 
pressure.
Betahistine, as a vasodilator, has been one of 
the first line drug for control of Meniere disease.6,7,8 
We found that it was effective in significantly reducing 
the number of vertigo attacks but it did not improve 
hearing and did not reduce the severity of vertigo 
and tinnitus score. A recent meta-analysis supports 
the therapeutic benefit of betahistine on vertiginous 
symptoms.22 Another meta-analysis, however, found 
no evidence that betahistine is effective in patients 
with Meniere disease or syndrome.9 Generally a dose 
of up to 24 mg/day is used. High dose of betahistine 
from 144 mg/day to between 288 and 480 mg/
day was well tolerated and found to be effective in 
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patients who did not sufficiently respond to lower 
dosages.23,24 
 It would have been better if the hearing 
outcome was assessed with audiogram. Many 
patients in our place do not come for follow up; 
we had to interview a few patients over phone to 
collect the data. Study of long term outcome with 
a larger study population would give more reliable 
knowledge about effectiveness of the treatment 
options.
CONCLUSION:
 We conclude from our study that diuretics 
were effective in improving number and severity of 
vertigo and tinnitus score though it was ineffective 
in improving the hearing outcome. Betahistine as a 
vasodilator was effective in reducing the numbers of 
vertigo but not the severity of vertigo, tinnitus score, 
and hearing improvement. We found dietary sodium 
restriction to be ineffective in improving any of the 
parameters of Meniere disease.
Conflict of Interest: None declared.
Financial Interest: None declared.
REFERENCES:
1. Committee on Hearing and Equilibrium guidelines for the 
diagnosis and evaluation of therapy in Meniere’s disease. 
American Academy of Otolaryngology-Head and Neck 
Foundation, Inc. Otolaryngol Head Neck Surg. 1995;113: 
181–5.
2. Rauch SD. Clinical hints and precipitating factors in 
patients suffering from Ménière’s disease. Otolaryngol Clin 
North Am. 2010;43(5):1011–7.
3. Gates G. Ménière’s disease: medical therapy. Harris JP, 
ed. Ménière’s Disease. The Hague, Netherlands: Kugler 
publications; 1999, 329–40 p.
4. Ha SK. Dietary salt intake and hypertension. Electrolyte 
Blood Press. 2014;12(1):7–18.
5. Burgess A, Kundu S. Diuretics for Ménière’s disease or 
syndrome. Cochrane Database of Systematic Reviews. 
2006, Issue 3. CD003599.
6. Gurkov R, Flatz W, Keeser D, Strupp M, Ertl-Wagner 
B, Krause F. Effect of standard-dose Betahistine on 
endolymphatic hydrops: an MRI pilot study. Eur Arch 
Otorhinolaryngol. 2013;270:1231–5.
7. Westhofen M. Meniere’s disease: evidence and 
controversies. HNO. 2009;57:446–54.
8. Smith WK, Sankar V, Pfleiderer AG. A national survey 
amongst UK otolaryngologists regarding the treatment of 
Meniere’s disease. J Laryngol Otol. 2005; 119:102–5.
9. James A, Burton MJ. Betahistine for Ménière’s disease or 
syndrome. Cochrane Database of Systematic Reviews. 
2001, Issue 1. CD001873. DOI: 10.1002/14651858.
CD001873.
10. Gregory JB, Giant CL, Steven AT. Comparison of 
Second-Echelon Treatments for Ménière’s Disease. 
JAMA Otolaryngol Head Neck Surg. 2014;140(8):754-61. 
doi:10.1001/jamaoto.2014.1249.
11. James AL, Burton ML. Betahistine for Ménière’s disease or 
syndrome. Cochrane Database of Systematic Reviews 2001, 
Issue 3. [Art. No.: CD001873. DOI: 10.1002/14651858.
CD001873]
12. Alexander TH, Harris JP. Current Epidemiology of 
Meniere’s Syndrome. Otolaryngologic Clinics of North 
America. 2010 Oct;43(5):965–70.
13. Simo H, Yang S, Qu W, Preis M, Nazzal M, Baugh R. Meniere’s 
disease: importance of socioeconomic and environmental 
factors. Am J Otolaryngol. 2015 Jun;36(3):393–8.
14. Luxford E, Berliner KI, Lee J, Luxford WM. Dietary 
Modification as Adjunct Treatment in Ménière’s Disease: 
Patient Willingness and Ability to Comply. Otology & 
Neurotology. 2013 Oct;34(8):1438–43.
15. Sheahan SL, Fields B. Sodium dietary restriction, 
knowledge, beliefs, and decision-making behavior of older 
females. J Am Acad Nurse Pract. 2007;20:217-24.
16. Minor LB, Schessel DA, Carey JP. Meniere’s disease. Curr 
Opin Neurol. 2004;17(1):9–16.
17. Smith WK, Sankar V, Pfleiderer AG. A national survey 
amongst UK otolaryngologists regarding the treatment of 
Meniere’s disease. J Laryngol Otol. 2005;119(2):102–5.
18. Khan BH, Ahmed Z, Khan RA. Effects of diuretics and 
vasodilators therapy in Meniere’s disease. Biomedica. 
2011:27; 114-8.
19. Chung SW, Cho CH, Han GC. Hearing and Dizziness in 
Patients with Definite Meniere's Disease after the Long 
Term Use of Diuretics. Journal of International Advanced 
Otology. 2010;6(2):188-94.
20. Berlinger NT. Meniere's disease: new concepts, new 
treatments. Minnesota medicine. 2011 Nov;94(11):33.
21. Fiorino F, Mattellini B, Vento M, Mazzocchin L, Bianconi 
L, Pizzini FB. Does the intravenous administration of 
frusemide reduce endolymphatic hydrops? The Journal of 
Laryngology & Otology. 2016 Mar;130(03):242–7.
22. Nauta JJ. Meta-analysis of clinical studies with betahistine 
in Meniere's disease and vestibular vertigo. European 
Archives of Oto-Rhino-Laryngology. 2014;271(5):887-97.
23. Lezius F, Adrion C, Mansmann U, Jahn K, Strupp M. High 
dosage betahistine dihydrochloride between 288 and 480 
mg/day in patients with severe Menière’s disease: a case 
series. European Archives of Oto-Rhino-Laryngology. 
2011 Aug;268(8):1237–40.
24. Albu S, Chirtes F, Trombitas V, Nagy A, Marceanu 
L, Babighian G, et al. Intratympanic dexamethasone 
versus high dosage of betahistine in the treatment of 
intractable unilateral Meniere disease. American Journal 
of Otolaryngology. 2015 Mar;36(2):205–9.
71
